相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Oncologist communication about emotion during visits with patients with advanced cancer
Kathryn I. Pollak et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The type 1 insulin-like growth factor receptor is over-expressed in bladder cancer
Mark A. Rochester et al.
BJU INTERNATIONAL (2007)
Implications for prostate cancer of insulin-like growth factor-I (IGF-I) genetic variation and circulating IGF-I levels
Mattias Johansson et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer
Stephen R. Plymate et al.
CLINICAL CANCER RESEARCH (2007)
The VHL tumor suppressor inhibits expression of the IGF1R and its loss induces IGF1R upregulation in human clear cell renal carcinoma
J. S. P. Yuen et al.
ONCOGENE (2007)
Phase I dose escalation study of the anti-insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors
Paul Haluska et al.
CLINICAL CANCER RESEARCH (2007)
Targeting the mTOR signaling network in cancer
Gary G. Chiang et al.
TRENDS IN MOLECULAR MEDICINE (2007)
Increased apoptosis and decreased proliferation of colorectal cancer cells using insulin-like growth factor binding protein-4 gene delivered locally by gene transfer
R. Durai et al.
COLORECTAL DISEASE (2007)
A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor-dependent tumor growth in vivo
Qun-Sheng Ji et al.
MOLECULAR CANCER THERAPEUTICS (2007)
AKT/PKB signaling: Navigating downstream
Brendan D. Manning et al.
CELL (2007)
A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors
A. W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I, first in man study of weekly IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumors
C. S. Higano et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor
Johann S. de Bono et al.
CLINICAL CANCER RESEARCH (2007)
Interfering with disease: a progress report on siRNA-based therapeutics
Antonin de Fougerolles et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells
Johann Riedemann et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1
Anthony W. Tolcher et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Picropodophyllotoxin or podophyllotoxin does not induce cell death via insulin-like growth factor-I receptor
Stig Linder et al.
CANCER RESEARCH (2007)
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis
Kai-Da Wu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Insulin-like growth factor type 1 receptor signaling in the cells of oligodendrocyte lineage is required for normal in vivo oligodendrocyte development and myelination
Martha Zeger et al.
GLIA (2007)
Essential role of insulin and insulin-like growth factor 1 receptor signaling in cardiac development and function
Palle G. Laustsen et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy
Donghua Yin et al.
CLINICAL CANCER RESEARCH (2007)
The role of the IGF system in cancer growth and metastasis: Overview and recent insights
Amir Abbas Samani et al.
ENDOCRINE REVIEWS (2007)
Insulin-like growth factor-I receptor signaling blockade combined with radiation
Gregory W. Allen et al.
CANCER RESEARCH (2007)
The role of insulin receptor isoforms and hybrid Insulin/IGF-I receptors in human cancer
Antonino Belfiore
CURRENT PHARMACEUTICAL DESIGN (2007)
Adult growth hormone deficiency: to treat or not to treat
M. Tzanela
EXPERT OPINION ON PHARMACOTHERAPY (2007)
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin
Hua Zhang et al.
CANCER RESEARCH (2007)
Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells
S. A. Byron et al.
BRITISH JOURNAL OF CANCER (2006)
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors
Jennifer D. Wu et al.
CLINICAL CANCER RESEARCH (2006)
Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs
A. H. Yeh et al.
ONCOGENE (2006)
Hybrid receptors formed by insulin receptor (IR) and insulin-like growth factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity irrespective of the IR splice variant
Rita Slaaby et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
The insulin-like growth factor-1 receptor inhibitor PPP produces only very limitedresistance in tumor cells exposed to long-term selection
D. Vasilcanu et al.
ONCOGENE (2006)
RNAi-mediated gene silencing in non-human primates
TS Zimmermann et al.
NATURE (2006)
Monoclonal antibody therapy
D O'Mahony et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2006)
Down-regulation of insulin receptor by antibodies against the type I insulin-like growth factor receptor: Implications for anti-insulin-like growth factor therapy in breast cancer
D Sachdev et al.
CANCER RESEARCH (2006)
The insulin-like growth factor-1 receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells
A Girnita et al.
CLINICAL CANCER RESEARCH (2006)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells
T Strömberg et al.
BLOOD (2006)
Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
E Menu et al.
BLOOD (2006)
Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor
Ana S. Martins et al.
CLINICAL CANCER RESEARCH (2006)
In vitro and in vivo antitumor effects of the dual insulin-like growth factor-I/insulin receptor inhibitor, BMS-554417
P Haluska et al.
CANCER RESEARCH (2006)
Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells
JF Youngren et al.
BREAST CANCER RESEARCH AND TREATMENT (2005)
Trastuzumab: updates and future issues
M Toi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade
YJ Shi et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Discovery of a 1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity
M Wittman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2005)
Inhibition of insulin-like growth factor-I receptor (IGF-IR) signaling and tumor cell growth by a fully human neutralizing anti-IGF-IR antibody
Y Wang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Blocking insulin-like growth factor-I receptor as a strategy for targeting cancer
F Hofmann et al.
DRUG DISCOVERY TODAY (2005)
Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases
IM Bell et al.
BIOCHEMISTRY (2005)
A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model
N Majeed et al.
ONCOGENE (2005)
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity
D Lu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors
K Scotlandi et al.
CANCER RESEARCH (2005)
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors
JD Wu et al.
CLINICAL CANCER RESEARCH (2005)
siRNA induced transcriptional gene silencing in mammalian cells
H Kawasaki et al.
CELL CYCLE (2005)
Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871
BD Cohen et al.
CLINICAL CANCER RESEARCH (2005)
The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy
GS Warshamana-Greene et al.
CLINICAL CANCER RESEARCH (2005)
Biomembrane-permeable and ribonuclease-resistant siRNA with enhanced activity
HT Liao et al.
OLIGONUCLEOTIDES (2005)
Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer
MA Rochester et al.
CANCER GENE THERAPY (2005)
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells
A Camirand et al.
BREAST CANCER RESEARCH (2005)
Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis
AG Renehan et al.
LANCET (2004)
Signaling by insulin-like growth factor 1 in brain
CA Bondy et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors
CS Mitsiades et al.
CANCER CELL (2004)
In vivo antitumor activity of NVP-AEW541 -: A novel, potent, and selective inhibitor of the IGF-IR kinase
C García-Echeverría et al.
CANCER CELL (2004)
The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110α) pathway
JR McMullen et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells
D Sachdev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors
M Goya et al.
CANCER RESEARCH (2004)
Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
HE Jones et al.
ENDOCRINE-RELATED CANCER (2004)
Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs
J Soutschek et al.
NATURE (2004)
Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth
A Girnita et al.
CANCER RESEARCH (2004)
The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway
D Vasilcanu et al.
ONCOGENE (2004)
Loss of tumorigenicity and metastatic potential in carcinoma cells expressing the extracellular domain of the type 1 insulin-like growth factor receptor
AA Samani et al.
CANCER RESEARCH (2004)
Advances in protein kinase B signalling:: AKTion on multiple fronts
DP Brazil et al.
TRENDS IN BIOCHEMICAL SCIENCES (2004)
Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics
G Blum et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma
A Hakam et al.
DIGESTIVE DISEASES AND SCIENCES (2003)
The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript
EA Bohula et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Pegvisomant: an advance in clinical efficacy in acromegaly
PM Stewart
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2003)
Inhibitory effect of adenovirus-uteroglobin transduction on the growth of lung cancer cell lines
JC Lee et al.
CANCER GENE THERAPY (2003)
Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers
M Letsch et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Chemosensitization of human prostate cancer using antisense agents targeting the type 1 insulin-like growth factor receptor
GO Hellawell et al.
BJU INTERNATIONAL (2003)
Role of the insulin-like growth factor I insulin receptor substrate 1 axis in Rad51 trafficking and DNA repair by homologous recombination
J Trojanek et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Cellular actions of the insulin-like growth factor binding proteins
SM Firth et al.
ENDOCRINE REVIEWS (2002)
Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved
G Pandini et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Inhibition of proliferation in human MNNG/HOS osteosarcoma and SK-ES-1 Ewing sarcoma cell lines in vitro and in vivo by antagonists of growth hormone-releasing hormone - Effects on insulin-like growth factor II
R Braczkowski et al.
CANCER (2002)
Structural biology of insulin and IGF1 receptors: Implications for drug design
P De Meyts et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
Effects of genetic blockade of the insulin-like growth factor receptor in human colon cancer cell lines
Y Adachi et al.
GASTROENTEROLOGY (2002)
Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis
T Lopez et al.
CANCER CELL (2002)
Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin)
YH Lu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2001)
Structure and autoregulation of the insulin-like growth factor 1 receptor kinase
S Favelyukis et al.
NATURE STRUCTURAL BIOLOGY (2001)
Downregulation of the type 1 insulin-like growth factor receptor in mouse melanoma cells is associated with enhanced radiosensitivity and impaired activation of Atm kinase
VM Macaulay et al.
ONCOGENE (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Chemical properties of catechols and their molecular modes of toxic action in cells, from microorganisms to mammals
N Schweigert et al.
ENVIRONMENTAL MICROBIOLOGY (2001)
Alterations in tumorigenicity of embryonal carcinoma cells by ICF-I triple-helix induced changes in immunogenicity and apoptosis
A Ly et al.
LIFE SCIENCES (2000)
Insulin-like growth factor 1 regulates the location, stability, and transcriptional activity of β-catenin
MP Playford et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Role of insulin receptors and IGF receptors in growth and development
KI Rother et al.
PEDIATRIC NEPHROLOGY (2000)
Structure and function of the type 1 insulin-like growth factor receptor
TE Adams et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2000)
Insulin-like growth factor physiology and cancer risk
M Pollak
EUROPEAN JOURNAL OF CANCER (2000)
Insulin-like growth factor-I receptors and estrogen receptors interact in the promotion of neuronal survival and neuroprotection
LM Garcia-Segura et al.
JOURNAL OF NEUROCYTOLOGY (2000)
Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo
CL Chernicky et al.
CANCER GENE THERAPY (2000)
分享论文
